<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00590473</url>
  </required_header>
  <id_info>
    <org_study_id>71692</org_study_id>
    <nct_id>NCT00590473</nct_id>
  </id_info>
  <brief_title>Sacral Neuromodulation in Patients With IC</brief_title>
  <official_title>Sacral Neuromodulation: Bilateral Placement vs. Unilateral Placement in Patients With Interstitial Cystitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Drexel University College of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Medtronic</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Drexel University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The hypothesis for this study is that bilateral sacral neuromodulation will improve symptoms&#xD;
      of interstitial cystitis by at least 25% when compared to unilateral sacral neuromodulation&#xD;
      as reported by patient's responses to the Interstitial Cystitis Symptom and Problem Indices.&#xD;
&#xD;
      This study will be a prospective randomized study comparing bilateral to unilateral sacral&#xD;
      neuromodulation. The study population will include all patients diagnosed with interstitial&#xD;
      cystitis, using the NIDDK criteria, having staged sacral neuromodulator stimulators placed at&#xD;
      Hahnemann University Hospital.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2007</start_date>
  <completion_date type="Actual">February 2009</completion_date>
  <primary_completion_date type="Actual">February 2009</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To determine if bilateral sacral neuromodulation will reduce the patient's score on the Interstitial Cystitis Symptom and Problem Questionnaire by at least 25% when compared to unilateral sacral neuromodulation in patients with interstitial cystitis.</measure>
    <time_frame>Post-op, at 6 weeks and at 3 months post-surgery</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To determine if bilateral sacral neuromodulation will improve the patient's voiding diary defined as reduction in urinary frequency by 25% from baseline when compared to unilateral sacral neuromodulation in patients with interstitial cystitis</measure>
    <time_frame>Post-op, at 6 weeks and 3 months post-surgery</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">32</enrollment>
  <condition>Interstitial Cystitis</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Unilateral Placement of Interstim IPG</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Bilateral Placement of Interstim IPG</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Interstim</intervention_name>
    <description>Unilateral vs. Bilateral Placement of Interstim IPG</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Female&#xD;
&#xD;
          -  Diagnosis of interstitial cystitis for at least 6 months.&#xD;
&#xD;
          -  At least 18yrs old and less than 80.&#xD;
&#xD;
          -  Symptoms of urgency (&gt;4 on the visual analog scale).&#xD;
&#xD;
          -  Symptoms of urinary frequency (&gt;8 episodes/day as recorded on a voiding diary)&#xD;
&#xD;
          -  Symptoms of pelvic pain (&gt;4 on the visual analog scale for pelvic pain).&#xD;
&#xD;
          -  Interstitial Cystitis refractory to more conservative treatments such as behavioral&#xD;
             modification, dietary intervention, or medical therapy for at least 6 months.&#xD;
&#xD;
          -  Able to make medical decisions for herself.&#xD;
&#xD;
          -  Presence of either glomerulations of Hunner's ulcer on cystoscopic examination.&#xD;
&#xD;
          -  Participant must agree to use a medically acceptable method of contraception&#xD;
             throughout the entire study period, and for 7 days after the study period. Medically&#xD;
             acceptable methods of contraception include abstinence, birth control pills or&#xD;
             patches, diaphragm with spermicide, IUD, condom with vaginal spermicide, surgical&#xD;
             sterilization, post menopausal for at least 1 year, implants or injections, or&#xD;
             vasectomized partner.&#xD;
&#xD;
          -  Must give written informed consent to participate in this study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Prior sacral neuromodulation.&#xD;
&#xD;
          -  Participant is currently pregnant or breastfeeding.&#xD;
&#xD;
          -  Male.&#xD;
&#xD;
          -  Urinary retention (defined by post void residual greater than 100cc).&#xD;
&#xD;
          -  Neurologic deficit.&#xD;
&#xD;
          -  Need for future MRI surveillance.&#xD;
&#xD;
          -  Involved in any study within the past thirty days or currently enrolled.&#xD;
&#xD;
          -  Presence of bladder or ureteral calculi.&#xD;
&#xD;
          -  Active genital herpes.&#xD;
&#xD;
          -  Uterine, cervical, vaginal, or urethral cancer.&#xD;
&#xD;
          -  Urethral diverticulum.&#xD;
&#xD;
          -  Cyclophosphamide cystitis.&#xD;
&#xD;
          -  Vaginitis.&#xD;
&#xD;
          -  Tuberculous cystitis.&#xD;
&#xD;
          -  Foreign body within the bladder (indwelling catheter- foley or suprapubic tube, or&#xD;
             ureteral stent).&#xD;
&#xD;
          -  An employee or a relative of an employee of Medtronic Inc. or The Pelvic and Sexual&#xD;
             Health Institute.&#xD;
&#xD;
          -  Bladder capacity greater than 350 cc while awake during cystometrogram.&#xD;
&#xD;
          -  Duration of symptoms of less than 6 months.&#xD;
&#xD;
          -  Detrusor overactivity on cystometrogram.&#xD;
&#xD;
          -  Absence of nocturia, defined by greater than 2 voids per sleeping hours.&#xD;
&#xD;
          -  Urinary symptoms relieved by either antimicrobials, antiseptics, anticholinergics, or&#xD;
             antispasmodics.&#xD;
&#xD;
          -  Urinary frequency of less than 8 voids per day.&#xD;
&#xD;
          -  Diagnosis of bacterial cystitis or prostatitis within the past 3 months.&#xD;
&#xD;
          -  Radiation cystitis.&#xD;
&#xD;
          -  Benign or malignant bladder tumors.&#xD;
&#xD;
          -  Age less than 18 or greater than 79.&#xD;
&#xD;
          -  Participant is currently receiving or has received pelvic radiation.&#xD;
&#xD;
          -  Participant is diagnosed with cancer within the past 5 years prior to the start of the&#xD;
             study.&#xD;
&#xD;
          -  Participant has a history of alcohol or substance abuse within the past 5 years prior&#xD;
             to the start of the study.&#xD;
&#xD;
          -  Severe or uncontrolled diabetes or diabetes with peripheral nerve involvement.&#xD;
&#xD;
          -  Patients with implanted electrical devices (cardiac pacemakers or defibrillators).&#xD;
&#xD;
          -  Patients on anticoagulation therapy.&#xD;
&#xD;
          -  Planned future exposure to diathermy, microwave, or RF energy.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>79 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kristene E. Whitmore, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Drexel University College of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pelvic and Sexual Health Institute</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2017</verification_date>
  <study_first_submitted>December 26, 2007</study_first_submitted>
  <study_first_submitted_qc>December 26, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 10, 2008</study_first_posted>
  <last_update_submitted>April 7, 2017</last_update_submitted>
  <last_update_submitted_qc>April 7, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 10, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Interstitial Cystitis</keyword>
  <keyword>IC</keyword>
  <keyword>Neuromodulation</keyword>
  <keyword>Interstim Therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cystitis</mesh_term>
    <mesh_term>Cystitis, Interstitial</mesh_term>
  </condition_browse>
  <pending_results>
    <submitted>April 12, 2017</submitted>
    <returned>May 19, 2017</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

